» Articles » PMID: 16187942

Resetting the Functional Capacity of Regulatory T Cells: a Novel Immunotherapeutic Strategy to Promote Immune Tolerance

Overview
Specialties Biology
Pharmacology
Date 2005 Sep 29
PMID 16187942
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Over the last few years, there has been a re-emergence of the concept of suppressor/regulatory T cells among the central players of immune mechanisms controlling a wide variety of immune responses from physiological autoreactivity (i.e., response to self-antigens) to responses to transplants, tumours and infectious antigens. Regulatory T cells are diverse in their phenotypes, antigen specificity, mode of action and immunopathological relevance. This review briefly summarises studies from the authors' group showing that specialised subsets of regulatory T cells are instrumental in the control of autoimmune diseases and more specifically of Type 1 diabetes. In addition, this review will provide evidence supporting the notion that CD3-specific monoclonal antibodies are representatives of a new category of immunotherapeutic agents that possess the unique capacity to promote immunological tolerance (an antigen-specific unresponsiveness in the absence of long-term generalised immunosuppression) through their ability to induce immunoregulatory T cells.

Citing Articles

Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes.

Jorns A, Akin M, Arndt T, Terbish T, Zu Vilsendorf A, Wedekind D J Mol Med (Berl). 2014; 92(7):743-55.

PMID: 24599515 DOI: 10.1007/s00109-014-1137-2.


Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice.

Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman M, Skidgel R PLoS One. 2009; 4(1):e4226.

PMID: 19156219 PMC: 2627485. DOI: 10.1371/journal.pone.0004226.